Analysis of irrational fixed dose combinations in the Indian drug market using the WHO guidelines

2022 ◽  
Vol 12 (8) ◽  
pp. 1
Author(s):  
Anshul Jhanwar
Keyword(s):  
Drug Market ◽  
Fixed Dose ◽  
Who Guidelines

scholarly journals The irrational fixed dose combinations in the Indian drug market: an evaluation of prescribing pattern using WHO guidelines

2013 ◽  
Vol 2 (4) ◽  
pp. 452 ◽  
Author(s):  
Somesh Rayasam ◽  
Sujata Dudhgaonkar ◽  
Ganesh Dakhale ◽  
Rohan Hire ◽  
Prashant Deshmukh ◽  
...  
Keyword(s):  
Drug Market ◽  
Fixed Dose ◽  
Who Guidelines ◽  
Prescribing Pattern

3D printing in pharmacy

2020 ◽  
pp. 58-60
Author(s):  
Yuliya Prozherina ◽  
Keyword(s):  
3D Printing ◽  
Cost Effective ◽  
Drug Market ◽  
Dosage Forms ◽  
Fixed Dose ◽  
Major Step ◽  
Combination Drugs ◽  
Effective Technology ◽  
Dose Combination ◽  
Research Stage

3D printing of drugs is an innovative and cost-effective technology, which is a major step towards personalized medicine. This technology can be used for the development of controlled-release drugs; fixed-dose combination drugs, as well as for the creation of orodispersible dosage forms. The global 3D drug market is still largely at the research stage, but its rapid growth is expected in the coming decade [1].

scholarly journals Ipertensione arteriosa polmonare: stima della casistica italiana e considerazioni sull’impatto sul budget dell’introduzione di tadalafil

2010 ◽  
Vol 11 (2) ◽  
pp. 77-82
Author(s):  
Luca Guidi ◽  
Mariano Alejandro Mignini
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Budget Impact ◽  
Drug Market ◽  
Fixed Dose ◽  
International Literature ◽  
Daily Cost ◽  
Dose Administration ◽  
Number Of Patients ◽  
Wide Range ◽  
Pulmonary Arterial

This contribution is an attempt to estimate a range of Pulmonary Arterial Hypertension (PAH) prevalence in Italy using international literature and Italian drug market sales data and to evaluate the budget impact of the introduction of tadalafil among the actual drugs with specific indication for this pathology. The final epidemiological figure obtained shows a wide range of prevalence of PAH in Italy (900-3,000 cases). The introduction of tadalafil as PAH treatment should not cause a cost increase for the pharmaceutical budget considering that this new therapy will occupy essentially the patient segment actually treated with sildenafil and that it reduces, in a significant number of patients, the daily cost of PAH therapy through a stable, fixed dose, administration.

Sign in / Sign up

Export Citation Format

Share Document